[go: up one dir, main page]

Chen, 2022 - Google Patents

Outsmarting and Outmuscling Cancer Cells for Next-Generation CAR-T Cell Therapies

Chen, 2022

View PDF
Document ID
8496052716640879450
Author
Chen L
Publication year

External Links

Snippet

CAR-T cell therapy has emerged as a promising cancer treatment modality with curative potential. In this therapeutic regime, T cells are isolated from patient blood, genetically engineered to express tumor-targeting chimeric antigen receptors (CARs), and re-infused …
Continue reading at escholarship.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Similar Documents

Publication Publication Date Title
US20230257776A1 (en) Methods and compositions for transducing lymphocytes and regulating the activity thereof
CN111479921B (en) Methods and compositions for genetically modifying and amplifying lymphocytes and modulating their activity
EP3589733B1 (en) Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
EP3472318B1 (en) Methods and compositions for transducing lymphocytes and regulating the activity thereof
Han et al. Masked chimeric antigen receptor for tumor-specific activation
JP7217970B2 (en) Compositions and methods for reprogramming T-cell receptors using fusion proteins
US10239948B2 (en) Method of engineering multi-input signal sensitive T cell for immunotherapy
EP3071222B1 (en) Cell
ES2857226T3 (en) Regulable chimeric antigen receptor
JP2020195393A (en) Engineered cells for adoptive cell therapy
US20200397821A1 (en) Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
KR20210132105A (en) Hypoxia-Reactive Chimeric Antigen Receptor
US20240390497A1 (en) Compositions of chimeric antigen receptor (car) signaling molecules and uses thereof
Obajdin et al. Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells
US20230392139A1 (en) Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
Chen Outsmarting and Outmuscling Cancer Cells for Next-Generation CAR-T Cell Therapies
JP2023543556A (en) Chimeric antigen receptor (CAR) with CD28 transmembrane domain
Drabble Enhancing CAR T Cell Therapy with NKG2D CAR NK Cells to Improve Efficacy Against B cell Leukaemia
Brog Souped-up Cars: Engineering Novel Recognition and Improving Efficacy for Solid Tumors
Li et al. Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy
Labanieh Enhancing the Safety and Efficacy of Engineered Cell Therapies using Protease-Regulated Platforms
HK40111732A (en) Compositions of chimeric antigen receptor (car) signaling molecules and uses thereof
CN119894923A (en) Chimeric antigen receptor comprising TMIGD2 costimulatory domains and related methods of use
HK40007848B (en) Methods and compositions for transducing lymphocytes and regulating the activity thereof
HK40007848A (en) Methods and compositions for transducing lymphocytes and regulating the activity thereof